These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 16253869)

  • 21. How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation.
    Reed SD; Califf RM; Schulman KA
    Health Aff (Millwood); 2006; 25(5):1309-17. PubMed ID: 16966727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The promise of South African biotech.
    Akermann B; Kermani F
    Drug Discov Today; 2006 Nov; 11(21-22):962-5. PubMed ID: 17055404
    [No Abstract]   [Full Text] [Related]  

  • 23. [Biopharmaceutical industry's commitment to innovation and to the future of health care].
    Marini G
    Recenti Prog Med; 2006 Nov; 97(11):626-33. PubMed ID: 17252719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strategic considerations for the biotechnology business to the year 2000.
    Cometta S
    Arzneimittelforschung; 1989 Aug; 39(8):929-34. PubMed ID: 2818683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biotech jostles with pharma for slice of HIV market.
    Katsnelson A
    Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
    [No Abstract]   [Full Text] [Related]  

  • 26. Profiles of four top biotech companies in India.
    Suresh N; Rao ChS
    Biotechnol J; 2009 Mar; 4(3):295-300. PubMed ID: 19296435
    [No Abstract]   [Full Text] [Related]  

  • 27. Biotech business Down Under.
    Beckley C
    Nature; 2004 Jun; 429(6991 Suppl):5-9. PubMed ID: 15175704
    [No Abstract]   [Full Text] [Related]  

  • 28. Swiss star finds it tough at the top.
    Nature; 2005 Dec; 438(7068):557. PubMed ID: 16319858
    [No Abstract]   [Full Text] [Related]  

  • 29. Biotech round the world: focus on Canada.
    Biotechnol J; 2008 Jul; 3(7):848-51. PubMed ID: 18624341
    [No Abstract]   [Full Text] [Related]  

  • 30. Innovation and compliance are not diametrically opposed.
    Raab GK
    Qual Assur; 1994 Mar; 3(1):2-8. PubMed ID: 7804614
    [No Abstract]   [Full Text] [Related]  

  • 31. Building for an exit (or not).
    Gunning TG
    Nat Biotechnol; 2008 Sep; 26(9):971-3. PubMed ID: 18792427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medical entrepreneurism: the current opportunity in America.
    Lexa FJ
    J Am Coll Radiol; 2004 Oct; 1(10):762-8. PubMed ID: 17411697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early-stage returns?
    Booth BL
    Nat Biotechnol; 2006 Nov; 24(11):1335-40. PubMed ID: 17093473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Doing better at doing good.
    Nat Biotechnol; 2008 Apr; 26(4):357. PubMed ID: 18391995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost containment: Europe. Switzerland.
    de Torrenté A; Chioléro R; Suter PM
    New Horiz; 1994 Aug; 2(3):345-9. PubMed ID: 8087595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bonsai biotech.
    Bains W
    Nat Biotechnol; 2009 Mar; 27(3):233. PubMed ID: 19270667
    [No Abstract]   [Full Text] [Related]  

  • 37. Europe caught in innovation quagmire.
    Mitchell P
    Nat Biotechnol; 2005 Sep; 23(9):1029. PubMed ID: 16151378
    [No Abstract]   [Full Text] [Related]  

  • 38. The three pillars of bioentrepreneurship.
    Schoemaker HJ; Schoemaker AF
    Nat Biotechnol; 1998 May; 16 Suppl():13-5. PubMed ID: 9591253
    [No Abstract]   [Full Text] [Related]  

  • 39. BIO 2006 Annual International Convention. Innovations in biotech in China and Italy.
    Tear S; Zarkowska T
    IDrugs; 2006 Jun; 9(6):386-9. PubMed ID: 16752303
    [No Abstract]   [Full Text] [Related]  

  • 40. Getting real about valuations in biotech.
    Villiger R; Bogdan B
    Nat Biotechnol; 2005 Apr; 23(4):423-8. PubMed ID: 15815665
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.